Physician profile
Debra E Andvik
NPI 1821172404
$2,744.65
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,363 · 2022: $861 · 2023: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $478.81 | 2021-2023 | Repatha, Otezla, Evenity |
| Abbvie INC. | $402.85 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $250.77 | 2021-2023 | Gardasil 9, Vaxneuvance, Verquvo |
| Astrazeneca Pharmaceuticals Lp | $241.21 | 2021-2023 | Breztri |
| Astellas Pharma US INC | $221.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.83 | 2021-2023 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $141.42 | 2022-2023 | |
| Lilly USA, LLC | $119.81 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $102.93 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $66.38 | 2021 | |
| Pfizer INC. | $65.29 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $64.56 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.23 | 2022 | |
| Hologic Sales and Service, LLC | $51.25 | 2021 | |
| Amarin Pharma, INC. | $51.24 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.30 | 2021-2023 | |
| Grifols USA, LLC | $30.84 | 2022-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $29.32 | 2022 | |
| Exeltis, USA INC. | $27.47 | 2021 | |
| Lundbeck LLC | $23.52 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $19.58 | 2022 | |
| Alkermes, INC. | $18.66 | 2023 | Aristada, Lybalvi |
| Medicure Pharma INC. | $17.30 | 2021 | |
| Sanofi Pasteur INC. | $15.22 | 2021 | |
| Mylan Specialty L.P. | $13.80 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Andvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.